 | | Vol. 8.45 – 2 December, 2020 |
| |
|
|
| Researchers studied hundreds of hospitalized—and closely monitored—patients with cancer receiving haematopoietic cell transplantation as they recover from chemotherapy and stem-cell engraftment.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| SARS-CoV-2 could enter the nervous system by crossing the neural–mucosal interface in olfactory mucosa, exploiting the close vicinity of olfactory mucosal, endothelial and nervous tissue, including delicate olfactory and sensory nerve endings.
[Nature Neuroscience] |
|
|
|
| Scientists developed nanoparticle vaccines by covalently conjugating the self-assembled 24-mer ferritin to the receptor binding domain and/or heptad repeat subunits of the SARS-CoV-2 spike protein.
[Immunity] |
|
|
|
| Researchers utilized SARS-CoV-2-reactive CD4+ T cell enrichment to examine the antigen-avidity and clonality of these cells, as well as the relative contribution of common cold corona virus cross-reactivity.
[Immunity] |
|
|
|
| To determine whether D614G might mediate neutralization-escape that could compromise vaccine efficacy, sera from Spike-immunized mice, nonhuman primates and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 spike.
[Cell Host & Microbe] |
|
|
|
| Investigators identified panels of fully human monoclonal antibodies from large phage-displayed Fab, scFv, and VH libraries by panning against the receptor binding domain of the SARS-CoV-2 spike glycoprotein.
[Proceedings of the National Academy of Sciences of the United States of America] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists designed a simple microbial community with three strains of E. coli that cyclically interacted through (i) the inhibition of protein production, (ii) the digestion of genomic DNA, and (iii) the disruption of the cell membrane.
[Nature Communications] |
|
|
|
| Researchers determined whether HIV infection of latent tuberculosis-infected subjects compromised the balanced Mycobacterium tuberculosis (TB)-specific T helper 17 response of recognized importance in anti-TB immunity.
[Cell Reports] |
|
|
|
| To investigate the role of nucleotide-binding oligomerization domain-like receptors in neutrophil homeostasis, researchers used Nlrp6 gene-deficient mice in a model of Klebsiella pneumoniae-induced pneumonia-derived sepsis.
[Mucosal Immunology] |
|
|
|
| Enterobacteriaceae broadly reactive T cells were prominent among in vitro primed T cells. These data point to the existence of immunodominant T cell epitopes shared among different Enterobacteriaceae species and targeted by T cells that were readily found in the pre‐immune repertoire and were clonally expanded in the memory repertoire.
[European Journal of Immunology] |
|
|
|
|
| Immunotherapeutic interventions, such as use of checkpoint inhibitors and adoptive T cell transfer, have shown promise but caution is needed in the management of immune reconstitution inflammatory syndrome, an exuberant immune response that can contribute to morbidity and death.
[Nature Reviews Neurology] |
|
|
|
| Scientists review the complete pathway of airborne transmission of SARS-CoV-2 from aerosol dispersion in air to subsequent biological uptake after inhalation.
[ACS Nano] |
|
|
|
| The authors review the latest molecular and cellular findings on the mucosal response to SARS-CoV-2 in the nasal cavity and in Nasopharynx-Associated Lymphoid Tissue, and analyze its impact in the subsequent course of COVID-19.
[Mucosal Immunology] |
|
|
|
|
| City of Hope has initiated a Phase I clinical trial that will test one of its investigational SARS-CoV-2 vaccines in healthy volunteers between the ages of 18 and 55 who have not had COVID-19.
[City of Hope] |
|
|
|
| SAB Biotherapeutics announced that the Biomedical Advanced Research and Development Authority and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense have awarded SAB $57.5 million in expanded scope for its DiversitAb™ Rapid Response Antibody Program contract for the manufacturing of SAB-185, the company’s clinical stage therapeutic candidate for COVID-19.
[SAB Biotherapeutics] |
|
|
|
| Bellerophon Therapeutics, Inc. announced that the independent Data Monitoring Committee has completed its pre-specified interim analysis from the first 100 patients randomized in the Phase III COViNOX study of INOpulse® for the treatment of COVID-19.
[Bellerophon Therapeutics, Inc. (Globe Newswire, Inc.)] |
|
|
|
|
| March 29 – April 1, 2021
Lake Maggiore, Italy |
|
|
|
|
|
| | University of Minnesota Medical School – Minneapolis, Minnesota, United States |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | University of Nantes – Nantes, France |
|
|
|
| | Queen’s University – Kingston, Ontario, Canada |
|
|
|
| | Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
